Morgan Stanley lowered the firm’s price target on GSK (GSK) to 1,355 GBp from 1,450 GBp and keeps an Underweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Pharma put volume heavy and directionally bearish
- GSK Executes Share Buyback on May 6, 2025
- Pharma imports to U.S. surged in March ahead of tariffs, Reuters says
- FDA announces expanded use of unannounced inspections at foreign facilities
- Largest borrow rate increases among liquid names